Fibresolve
Idiopathic Pulmonary Fibrosis (IPF) / Interstitial Lung Disease (ILD)
ApprovedActive
Key Facts
Indication
Idiopathic Pulmonary Fibrosis (IPF) / Interstitial Lung Disease (ILD)
Phase
Approved
Status
Active
Company
About Imvaria
Imvaria, founded in 2019 by physician-engineers from Google and Stanford, is a private, commercial-stage diagnostics company based in Berkeley, California. It has developed Fibresolve, the first FDA-authorized AI diagnostic tool for IPF/ILD, and is expanding its platform to other areas like lung cancer through a strategic collaboration with Mayo Clinic. The company operates a Digital Biomarker Lab, leveraging machine learning to create software-only biomarkers from complex clinical data, positioning it at the intersection of AI, radiology, and precision diagnostics.
View full company profile